Chapter 31. Fibrinolytic Therapy

  1. Salim Yusuf1,
  2. John A Cairns2,
  3. A John Camm3,
  4. Ernest L Fallen4 and
  5. Bernard J Gersh5
  1. James S Zebrack and
  2. Jeffrey L Anderson

Published Online: 4 OCT 2007

DOI: 10.1002/9780470986882.ch31

Evidence-based Cardiology, Second Edition

Evidence-based Cardiology, Second Edition

How to Cite

Zebrack, J. S. and Anderson, J. L. (2002) Fibrinolytic Therapy, in Evidence-based Cardiology, Second Edition (eds S. Yusuf, J. A. Cairns, A. J. Camm, E. L. Fallen and B. J. Gersh), BMJ Books, London, UK. doi: 10.1002/9780470986882.ch31

Editor Information

  1. 1

    Heart and Stroke Foundation of Ontario Research Chair, Senior Scientist of the Canadian Institute of Health Research, Director of Cardiology and Professor of Medicine, McMaster, University, Hamilton Health Sciences, Hamilton, Canada

  2. 2

    Dean, Faculty of Medicine, University of British Columbia, Vancouver, Canada

  3. 3

    Professor of Clinical Cardiology and Chief, Department of Cardiological Sciences, St George's Hospital Medical School, London, UK

  4. 4

    Professor Emeritus, McMaster University, Faculty of Health Sciences, Hamilton, Canada

  5. 5

    Consultant in Cardiovascular Diseases and Internal Medicine, Mayo Clinic; Professor of Medicine, Mayo Medical School, Rochester, Minnesota, USA

Publication History

  1. Published Online: 4 OCT 2007
  2. Published Print: 20 NOV 2002

ISBN Information

Print ISBN: 9780727916990

Online ISBN: 9780470986882



  • fibrinolytic therapy;
  • streptokinase;
  • anistreplase;
  • staphylokinase;
  • mortality


This chapter contains sections titled:

  • Impact, pathophysiology, and rationale

  • Early observational and controlled studies

  • Fibrinolytic agents

  • Efficacy of intravenous fibrinolytic therapy

  • Risks of thrombolytic therapy

  • Comparative fibrinolytic trials

  • Combinations of fibrinolytic therapy and glycoprotein IIb/IIIa receptor inhibitors or low molecular weight heparins

  • Combinations of fibrinolytic therapy and direct antithrombins

  • Indications for fibrinolytic therapy in AMI

  • Combinations of fibrinolytic therapy and direct antithrombins

  • Indications for fibrinolytic therapy in AMI

  • Current use of fibrinolytics

  • Selection of a fibrinolytic regimen